Active	Status	Sponsor type	Region	Phase	Filter
18 Active 9 Inactive 27 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yang, Yang
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer	Recruiting	3	560	RoW	Irinotecan Hydrochloride Injection, HX008, Placebo	Taizhou Hanzhong biomedical co. LTD	Stomach Cancer	08/23	08/23
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF	Terminated	3	372	Europe, US, RoW	Pamrevlumab, FG-3019, Placebo	FibroGen	Idiopathic Pulmonary Fibrosis	09/23	09/23
NCT05043688: Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.	Recruiting	3	426	RoW	Camrelizumab, radiotherapy	Zhigang Li, Jiangsu HengRui Medicine Co., Ltd.	Resectable Esophageal Squamous Cell Carcinoma	12/28	12/30
NCT05417321: A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors	Recruiting	1/2	80	US, RoW	HB0036, Anti-PD-L1 and anti-TIGIT bifunctional molecule	Shanghai Huaota Biopharmaceutical Co., Ltd.	Advanced Solid Tumor, NSCLC	08/25	08/25
Guoying, Wang
No trials found